{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:15:43Z","timestamp":1789600543187,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020021","name":"Avant Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacl.2024.08.012","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T21:57:15Z","timestamp":1725141435000},"page":"e946-e956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-7991","authenticated-orcid":false,"given":"Angela","family":"Burvill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2024.08.012_bib0001","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.08.012_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","article-title":"Population trends of recurrent coronary heart disease event rates remain high","volume":"4","author":"Briffa","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2024.08.012_bib0003","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.clinthera.2023.07.008","article-title":"The promise of PCSK9 and lipoprotein(a) as targets for gene silencing therapies","volume":"45","author":"Chan","year":"2023","journal-title":"Clin Ther"},{"issue":"20","key":"10.1016\/j.jacl.2024.08.012_bib0004","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"NEJM"},{"issue":"3","key":"10.1016\/j.jacl.2024.08.012_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.jacl.2024.08.012_bib0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","article-title":"Emerging use of early health technology assessment in medical product development: a scoping review of the literature","volume":"35","author":"Ijzerman","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacl.2024.08.012_bib0007","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacl.2024.08.012_bib0008","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"EHJ"},{"key":"10.1016\/j.jacl.2024.08.012_bib0009","first-page":"1192","article-title":"From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment","volume":"114","author":"Benn","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2024.08.012_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.012_bib0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modeling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jacl.2024.08.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001197","article-title":"National trends in recurrent AMI hospitalizations 1 year after acute myocardial infarction in Medicare beneficiaries: 1999\u20132010","volume":"3","author":"Chaudhry","year":"2014","journal-title":"JAHA"},{"key":"10.1016\/j.jacl.2024.08.012_bib0013","unstructured":"Australian Institute of Health and Welfare. General Record of Incidence of Mortality (GRIM) books. https:\/\/www.aihw.gov.au\/reports\/life-expectancy-deaths\/grim-books\/contents\/data-visualisation. [Accessed 25 Apr 2024]."},{"key":"10.1016\/j.jacl.2024.08.012_bib0014","first-page":"148","article-title":"Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction","volume":"13","author":"Thune","year":"2011","journal-title":"EJHF"},{"key":"10.1016\/j.jacl.2024.08.012_bib0015","unstructured":"Australian Government Department of Health and Aged Care. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Department of Health and Aged Care. Version: 5, 2016. https:\/\/pbac.pbs.gov.au. [Accessed 25 Apr 2024]."},{"issue":"6","key":"10.1016\/j.jacl.2024.08.012_bib0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.012_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","article-title":"Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction","volume":"2","author":"Lewis","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacl.2024.08.012_bib0018","unstructured":"Independent Health and Aged Care Pricing Authority (IHACPA). National Hospital Cost Data Collection report; Public Sector Report 2020-21. IHACPA. 2023. https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-sector-report-2020-21. [Accessed 25 Apr 2024]."},{"key":"10.1016\/j.jacl.2024.08.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modeling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacl.2024.08.012_bib0020","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)","volume":"10","author":"Chakraborty","year":"2022","journal-title":"AJPC"},{"key":"10.1016\/j.jacl.2024.08.012_bib0021","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s40273-020-00948-w","article-title":"Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: a cost-effectiveness analysis","volume":"38","author":"Kam","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacl.2024.08.012_bib0022","unstructured":"Australian Bureau of Statistics. Consumer price index all groups and health. https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/latest-release#data-downloads [Accessed 25 Apr 2024]."},{"key":"10.1016\/j.jacl.2024.08.012_bib0023","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2024.08.012_bib0024","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.jacl.2024.08.012_bib0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2024.08.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2020.05.007","article-title":"Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?","volume":"304","author":"Ademi","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.012_bib0027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacl.2024.08.012_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.08.012_bib0029","unstructured":"Australian Government Department of Health and Aged Care. Pharmaceutical benefits scheme. https:\/\/www.pbs.gov.au\/pbs\/home. [Accessed 25 Apr 2024]."},{"key":"10.1016\/j.jacl.2024.08.012_bib0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40273-020-00936-0","article-title":"Novel treatment strategies for secondary prevention of cardiovascular disease: a systematic review of cost-effectiveness","volume":"38","author":"Marquina","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacl.2024.08.012_bib0031","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2024.08.012_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2020.12.019","article-title":"2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia","volume":"319","author":"Svendsen","year":"2021","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T15:15:18Z","timestamp":1740669318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742400237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S193328742400237X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.08.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}